Phathom Pharmaceuticals (PHAT) Stock Forecast, Price Target & Predictions
PHAT Stock Forecast
Phathom Pharmaceuticals stock forecast is as follows: an average price target of $20.00 (represents a 168.46% upside from PHAT’s last price of $7.45) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
PHAT Price Target
The average price target for Phathom Pharmaceuticals (PHAT) is $20.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $12.00. This represents a potential 168.46% upside from PHAT's last price of $7.45.
PHAT Analyst Ratings
According to 11 Wall Street analysts, Phathom Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PHAT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Phathom Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Paul Choi | Goldman Sachs | $12.00 | $11.75 | 2.13% | 61.07% |
| Jul 19, 2024 | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | 155.82% | 275.84% |
| May 02, 2024 | Annabel Samimy | Stifel Nicolaus | $24.00 | $9.76 | 145.90% | 222.15% |
| Jan 05, 2024 | Joseph Stringer | Needham | $26.00 | $8.99 | 189.21% | 248.99% |
| Jan 04, 2023 | BMO Capital | $35.00 | $11.99 | 191.91% | 369.80% | |
| Jan 04, 2023 | Needham | $25.00 | $11.99 | 108.51% | 235.57% | |
| Nov 14, 2022 | BMO Capital | $38.00 | $10.65 | 256.81% | 410.07% | |
| Nov 11, 2022 | Guggenheim | $30.00 | $10.78 | 178.29% | 302.68% |
The latest Phathom Pharmaceuticals stock forecast, released on Aug 08, 2024 by Paul Choi from Goldman Sachs, set a price target of $12.00, which represents a 2.13% increase from the stock price at the time of the forecast ($11.75), and a 61.07% increase from PHAT last price ($7.45).
Phathom Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $22.50 |
| Last Closing Price | $7.45 | $7.45 | $7.45 |
| Upside/Downside | -100.00% | -100.00% | 202.01% |
In the current month, the average price target of Phathom Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Phathom Pharmaceuticals's last price of $7.45. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 05, 2024 | Needham | Buy | Buy | Hold |
| May 11, 2023 | William Blair | Market Perform | Downgrade | |
| May 11, 2023 | RBC Capital | Outperform | Upgrade | |
| May 11, 2023 | BTIG | Sell | Downgrade | |
| May 11, 2023 | Piper Sandler | Neutral | Downgrade | |
| May 11, 2023 | JMP Securities | Perform | Downgrade | |
| May 11, 2023 | Goldman Sachs | Sell | Downgrade | |
| May 11, 2023 | Evercore ISI | Outperform | Upgrade | |
| May 11, 2023 | Wells Fargo | Equal-Weight | Upgrade | |
| Jan 04, 2023 | BMO Capital | Outperform | Outperform | Hold |
| Jan 04, 2023 | Needham | Buy | Buy | Hold |
| Nov 14, 2022 | BMO Capital | Outperform | Outperform | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
| Aug 03, 2022 | Needham | Buy | Buy | Hold |
Phathom Pharmaceuticals's last stock rating was published by Goldman Sachs on Aug 08, 2024. The company gave PHAT a "Neutral" rating, the same as its previous rate.
Phathom Pharmaceuticals Financial Forecast
Phathom Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $682.00K | - |
| Avg Forecast | $54.50M | $49.16M | $38.26M | $28.02M | $26.04M | $12.61M | $5.68M | $1.63M | $400.89K | $211.00K |
| High Forecast | $60.36M | $54.45M | $42.37M | $29.67M | $29.40M | $12.71M | $5.68M | $1.63M | $443.98K | $211.00K |
| Low Forecast | $48.11M | $43.40M | $33.78M | $26.00M | $21.10M | $12.51M | $5.68M | $1.63M | $353.91K | $211.00K |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.70% | - |
Phathom Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.63M, with a low forecast of $1.63M, and a high forecast of $1.63M. PHAT's average Quarter revenue forecast represents a 138.95% increase compared to the company's last Quarter revenue of $682.00K (Dec 23).
Phathom Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $52.72M | $-37.78M |
| Avg Forecast | $32.70M | $29.50M | $22.96M | $16.81M | $15.62M | $7.57M | $3.41M | $977.79K | $240.54K | $-33.88M |
| High Forecast | $36.21M | $32.67M | $25.42M | $17.80M | $17.64M | $7.62M | $3.41M | $977.89K | $266.39K | $-27.11M |
| Low Forecast | $28.87M | $26.04M | $20.27M | $15.60M | $12.66M | $7.51M | $3.41M | $977.68K | $212.34K | $-40.66M |
| Surprise % | - | - | - | - | - | - | - | - | 219.18% | 1.11% |
1 analysts predict PHAT's average Quarter EBITDA for Mar 24 to be $977.79K, with a high of $977.89K and a low of $977.68K. This is -98.15% lower than Phathom Pharmaceuticals's previous annual EBITDA (Dec 23) of $52.72M.
Phathom Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $121.88M | $-43.42M |
| Avg Forecast | $-50.79M | $-60.12M | $-68.15M | $-77.18M | $-77.92M | $-94.92M | $-85.30M | $-85.35M | $-69.61M | $-36.47M |
| High Forecast | $-43.05M | $-50.96M | $-57.77M | $-65.42M | $-66.05M | $-80.45M | $-72.30M | $-72.34M | $-64.32M | $-29.18M |
| Low Forecast | $-57.88M | $-68.52M | $-77.67M | $-87.97M | $-88.81M | $-108.18M | $-97.22M | $-97.27M | $-74.91M | $-43.77M |
| Surprise % | - | - | - | - | - | - | - | - | -1.75% | 1.19% |
Phathom Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-85.35M, with a range of $-97.27M to $-72.34M. PHAT's average Quarter net income forecast represents a -170.03% decrease compared to the company's last Quarter net income of $121.88M (Dec 23).
Phathom Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $57.00M | $20.25M |
| Avg Forecast | $1.93B | $1.74B | $1.35B | $991.58M | $921.22M | $446.14M | $200.97M | $57.66M | $14.18M | $7.47M |
| High Forecast | $2.14B | $1.93B | $1.50B | $1.05B | $1.04B | $449.60M | $200.97M | $57.67M | $15.71M | $7.47M |
| Low Forecast | $1.70B | $1.54B | $1.20B | $919.96M | $746.51M | $442.67M | $200.96M | $57.66M | $12.52M | $7.47M |
| Surprise % | - | - | - | - | - | - | - | - | 4.02% | 2.71% |
Phathom Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $57.66M, based on 1 Wall Street analysts, with a range of $57.66M to $57.67M. The forecast indicates a 1.17% rise compared to PHAT last annual SG&A of $57.00M (Dec 23).
Phathom Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.14 |
| Avg Forecast | $-0.79 | $-0.93 | $-1.05 | $-1.19 | $-1.21 | $-1.47 | $-1.32 | $-1.32 | $-1.08 | $-0.97 |
| High Forecast | $-0.67 | $-0.79 | $-0.89 | $-1.01 | $-1.02 | $-1.24 | $-1.12 | $-1.12 | $-1.00 | $-0.97 |
| Low Forecast | $-0.90 | $-1.06 | $-1.20 | $-1.36 | $-1.37 | $-1.67 | $-1.50 | $-1.51 | $-1.16 | $-0.97 |
| Surprise % | - | - | - | - | - | - | - | - | -0.00% | 1.18% |
According to 1 Wall Street analysts, Phathom Pharmaceuticals's projected average Quarter EPS for Mar 24 is $-1.32, with a low estimate of $-1.51 and a high estimate of $-1.12. This represents a -55124.17% decrease compared to PHAT previous annual EPS of - (Dec 23).
Phathom Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| PHAT | Phathom Pharmaceuticals | $8.37 | $20.00 | 138.95% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $20.49 | $37.50 | 83.02% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |